“…Pharmacological approaches evaluated for METH addiction may interfere with the dopaminergic reward pathways, attenuate negative reinforcing effects of withdrawal, or improve psychiatric symptoms that impair chances of remaining abstinent . This leads to several types of medications that were tested in human laboratory paradigms and in Phase II clinical trials with different outcomes as follows: dexamphetamine, methylphenidate, modafinil (DA indirectly‐acting agonists), bupropion, mirtazapine (antidepressants), aripiprazole (antipsychotics), varenicline (nicotinic receptor partial agonist), rivastigmine (cholinesterase inhibitor), perindopril (angiotensin‐converting enzyme inhibitor IECA), ibudilast (a phosphodiesterase inhibitor; glial modulator), baclofen, gabapentin (GABAergic agents), topiramate (GABAergic/glutamatergic agent), naltrexone (opioid antagonist), n‐acetylcysteine (NAC, antioxidant), ondansetron (5‐HT3 receptor antagonist), passive immunization with monoclonal antibodies against METH (ie, vaccines) . Worley et al highlighted that mirtazapine, bupropion, and methylphenidate have shown some beneficial effect in phase II clinical trials, whereas mirtazapine and bupropion increased METH abstinence, and methylphenidate reduced METH craving and use and improved depressive symptoms.…”